Several retrospective studies have explored bevacizumab for EGFR mutant NSCLC patients who had oligoprogressive disease after first-line EGFR TKI therapy, but with rather limited data on third-generation EGFR TKI(Long et al., 2022; Yu et al., 2021; Xu et al., 2022). Here, EGFR is linked to non-small cell lung carcinoma.